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Summary COPD is characterised by damage to small airways due to an inflammatory
process as well as an imbalance between oxidants and antioxidants. Several
cytokines and cell adhesion molecules enhancing a mainly neutrophilic inflammation
have been associated with COPD. The aim of the study was to investigate whether
inflammation or oxidative markers gave an indication of the course of COPD during
an exacerbation.
Fourteen patients with moderate to severe COPD admitted to the St. Antonius
Hospital because of an exacerbation have been monitored during treatment with
prednisolone 50mg intravenously during 24 h at admission, reduced to 25mg at day 3
and tapered off with oral prednisolone at day 7. On three separate occasions, day 1,
3 and 7, H2O2 in exhaled air, IL-8 and the soluble cell adhesion molecule sICAM and
sE-selectin in serum were measured.
We compared the patients at day 1 with healthy controls (in both non-smokers and
smokers). Furthermore, we examined the changes from the study group in time
during therapy. At admission all the markers were raised in comparison with the
control groups. During treatment H2O2 concentrations in breath condensate declined
significantly (Po0.001) as well as IL-8 and sICAM in serum (P¼ 0.002, respectively,
Po0.001). There was no significant change in sE-selectin (P¼ 0.132). No significant
improvement has been found in spirometry.
These data suggest that the markers H2O2 in exhaled air, IL-8 and sICAM in serum
are suitable markers in monitoring exacerbated COPD.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) has
an increasing prevalence with high morbidity and
mortality. COPD intensity can vary in time; the
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progressively while smoking, recurrent exacerba-
tion and occupational or environmental pollution
accelerates this process.1
Airway inflammation and oxidative stress have
been implicated in the pathogenesis of COPD. The
inflammation in COPD shows high numbers of
neutrophils, macrophages and T-lymphocytes,
especially of the CD8 positive T cell subset in
bronchoalveolar lavage fluid.2,3 Induced sputum
revealed elevated levels of tumour necrosis factor-
a (TNF-a) and interleukin-8 (IL-8).4,5 IL-8 has been
detected in plasma of patients with COPD during an
acute phase response.6 IL-8 is a strong chemoat-
tractant of neutrophils, it also initiates degranula-
tion, production of reactive oxygen species (ROS)
and increased expression of cell adhesion molecule
CD1b/CD18 (MAC-1).7,8 Cell adhesion molecules are
major factors in recruitment, cumulating and site-
specific activation of inflammatory cells in the
airways.9–11 An increased expression of E-selectin
on endothelium and ICAM-1 on endothelium as well
as on epithelial surface has been associated with
COPD.12,13
Oxidative stress also plays an important role in
the pathogenesis of COPD. Oxidative stress is
caused by an imbalance between the production
of oxidants and the presence of antioxidants.
Oxidants are produced in the lungs by inflammatory
cells, especially neutrophils and macrophages.
There is strong evidence of an increased burden
of oxidants in the lungs of patients with stable
COPD.14,15 During an exacerbation the production
of ROS is increased presumable because of a large
burden of activated inflammatory cells in the lower
airways as a result of release of cytokines and
upregulation of cell adhesion molecules.7
An important exogenous source of oxidants in
COPD patients is cigarette smoke. An excess of ROS
can directly damage lung cells by oxidation of lipid
membranes, proteins and DNA. Besides, abundant
ROS cause inactivation of a1-antiprotease.
16
The level of oxidative stress may be used as an
indirect marker of airway inflammation. It can be
determined by measuring hydrogen peroxide (H2O2)
in exhaled breath condensate, a simple and non-
invasive procedure.17–24 Several investigators found
significant increased H2O2 levels in patients with
stable COPD compared to healthy non-smoking and
an additional increase in COPD patients with an
acute exacerbation.18,19,23,24
Our study aimed to investigate H2O2 in exhaled
air, IL-8 and the soluble cell adhesion molecules
sICAM-1 and sE-selectin in serum as suitable
markers for monitoring chronic obstructive pul-




Fourteen patients with a moderate to severe COPD
(FEV1o70% predicted, FEV1/FVCo70% and reversi-
bility to bronchodilators less than 10% of the
predicted value), admitted to the St. Antonius
Hospital because of an exacerbation, participated
the study. There were nine men and five women,
mean age 63.6 years (54–78). The diagnosis COPD
was made according to ATS standards.1 All subjects
had a history of smoking (430 packyears), four
were current smokers.
At admission there were no clinical signs of
respiratory bacterial tract infection or inflamma-
tion elsewhere. Before admission all except two
patients inhaled corticosteroids, six had a low
maintenance dose oral prednisolone (7.5–10mg)
and all were treated with inhaled short and/or long
acting b2-agonists, 11 patients had also received
anticholinergic inhalation therapy. Seven patients
used N-acetylcysteine and eight patients used slow-
release theophylline on regular base.
Patients with pulmonary disorders at present or
in the past other than COPD (e.g. tuberculosis,
bronchiectasis and asthma) were excluded.
All patients gave written informed consent to
participate in the study, which was approved by the
local Ethics Committee of the hospital.
Control group
The control group consisted of 15 healthy smoking
volunteers, eight men and seven women, mean age
44.4 years (20–57) and 15 healthy non-smoking
volunteers, six men and nine women, mean age
46.0 years (21–59) with normal spirometric test
[forced expiratory volume in 1 s (FEV1) and inspira-
tory vital capacity (IVC)] and no signs of infectious
disease during the past 4 weeks. All smoking
controls had a history of more than eight pack-
years. The non-smokers never smoked.
Study design
The samples were taken during 7 days before the
patient had breakfast between 8.30 and 9.30 a.m.;
on three separate occasions, day 1 (before or
shortly after start treatment), day 3 and day 7.
At admission all patients were treated with 50mg
prednisolone during 24 h; after 2–3 days the dose
was reduced to 25mg during 24 h and at day 7 all
subjects except one started a scheme of oral
prednisolone once a day. Theophylline as well as
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N-acetylcysteine were continued if previously used
and inhalation with b2-agonists and anticholinergics
was intensified. None of the patients smoked
cigarettes during admission.
On three separate occasions, day 1 (before or
shortly after start treatment), day 3 and day 7
(during treatment) spirometric tests were per-
formed. Within 60min after the spirometric test
the collection of H2O2 in exhaled breath conden-
sate and IL-8, sICAM-1 and sE-selectin in serum was
performed.
Collection and measurement of exhaled H2O2
Before collection a mouthwash was performed
using 15ml chlorohexidine (0.2%) during 1min to
eliminate contamination of expired breath by
mouth flora. The exhaled breath condensate
samples were taken between 8.30 and 9.30 a.m.
The patient was spontaneously breathing through a
mask with a two way valve (Downs CPAP Mask, Vital
Signs Inc., USA) for a 20min period. The expired
breath condensate was collected by passing the
exhaled air through a specially constructed collect-
ing device which consist of a 140 cm cold finger
with an internal diameter of 15mm. At the end of
the coldfinger, the condensate was collected into a
small glascontainer. This device was placed in a
polystyrene foam container filled with ice, water
and salt (21C to 51C). A second collecting device
was coupled to the first device to be sure that all
the exhaled breathe did indeed condensate. After
collection the condensate was immediately trans-
ported to the laboratory in a light protected vial
and stored at 701C and processed within 7 days.
The device was cleaned with distilled water each
time before and after the measurement.
H2O2 concentrations were measured in expired
breath condensate of the patients as described by
Gallati and Pracht.25 Two hundred microlitre breath
condensate or standard H2O2 (Sigma-Aldrich Com-
pany, Milwaukee, USA) was incubated in a micro-
titerplate well with 20 ml 1.155mmol/l 3,30–5,50-
tetramethylbenzidin (Sigma-Aldrich Company, Mil-
waukee, USA) in 1.155mol/l citric acid buffer pH
3.95 and 10 ml 52.5 U/ml horseradish peroxidase
(Sigma-Aldrich Company, Milwaukee, USA) for
25min in the dark at room temperature. Subse-
quently the mixture was acidified to a pH of 1 with
10 ml of 18 N sulphuric acid. The reaction product
was measured spectrofotometrically at 450 nm
using an automated Benchmark microplate reader
(Bio-Rad Laboratories, Hercules, USA). The absor-
bance is directly proportional to the concentration
of H2O2.
The detection limit of H2O2 in this method is
0.11 mmol/l. The intra-assay variability are 13.3%,
6.7% and 2.3% for standard solutions of 0.1, 0.25
and 0.5 mmol/l H2O2 (n¼ 10), respectively. The
stability of H2O2 in breath condensate is 10 days
with an inter-assay variability over time, to check
the storage of H2O2 in breath condensate at 801C,
from 3.7% (n¼ 5, day 1,4,7,10).
IL-8 assay: The IL-8 is a solid-phase, two-site
chemiluminescent immunometric assay measured
on the Immulite analyser (DPC, Los Angeles, USA).
The detection limit of IL-8 is 2.0 ng/l (duplicate CV
of the control group 5.4%; n¼ 10) with a reference
value of o8.9 ng/l.
Human soluble ICAM-1 and E-selectin assay: Both
tests are solid phase enzyme-linked immunosorbent
assays based on the sandwich principle (Hycult
biotechnology, Uden, The Netherlands) measured
on a automated microplate reader (Benchmark,
BIO-RAD, Veenendaal, The Netherlands). The de-
tection limit of ICAM-1 is 0.10 mg/l (duplicate CV of
the control group 3.6%, n¼ 10) with a reference
values of 39–165 mg/l and 0.05 mg/l (duplicate CV of
the control group 4.3%; n¼ 10) with a reference
interval of o27.2 mg/l for E-selectin.
Lung function measurements: FEV1 and vital
capacity (IVC) were measured using a dry spirom-
eter (MasterScreen, Jaeger Benelux, Amsterdam,
The Netherlands). Values were expressed as
percentage of predicted according to the ATS-
standards.1
Sputum sampling and culture: At admission
sputum was sampled in all patients. The investiga-
tion of sputum was performed on an aliquot of a
fresh obtained spontaneous sputum sample by an
experienced microbiology technician and according
to its predominant macroscopic appearance judged
as mucoid or purulent. Direct examination using the
Gram stain technique was applied to judge the
quality of the sputum. If the quality of the sputum
was sufficient a culture was made, and the number
of bacteria in the sputum was semi-quantitatively
assessed after culture appears to be positive from
þ / till 4þ . If the sputum sample was not
sufficient a new sample was taken.
Statistical analysis
Data analysis was performed using SPSS software
version 11.0. Results are reported as median [25–75
percentiles]. Comparisons between groups were
carried out using the non-parametric Mann–Whit-
ney test. Statistical evaluation of the patient group
before and during treatment was done with the
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non-parametric Friedman test. A p-value o0.05
was considered significant.
Results
From the 14 sputum cultures five patients had a
positive culture. Three patients had isolated
Haemophilus influenza and two patients had a
culture with Streptococcus pneumoniae as well as
Haemophilus influenza, respectively, Moraxella
catarrhalis as well as Haemophilus influenza.
However, none of these patients had evidence of
an infection at admission, the X-ray showed no
signs of an infection, the C-reactive protein and
white blood cell count were in the normal range.
Neither received antibiotics during the observation
period despite six positive sputum cultures in
retrospect.
At admission high levels of exhaled H2O2 were
found in all patients. The median values before
treatment were significantly higher compared with
the two control groups, smokers and non-smokers
(Po0.001 for both control groups versus patient
group). During treatment the median concentra-
tions declined significantly (P¼ 0.001) (Fig. 1A,
Table 1). There was also a significance between
both control groups (Po0.001 for smokers versus
non-smokers; Table 2; Fig. 2).
Serum IL-8 before treatment was significantly
elevated in comparison with the control groupn
(Po0.001). The median values decreased signifi-
cantly during treatment (P¼0.002) (Fig. 1B, Table
1).
sICAM-1 in serum before treatment was higher
compared with the control groupG but differed not
significant (P¼ 0.174). During treatment there was
a significant decline of median values (Po0.001)
(Fig. 1C, Table 1).
sE-selectin in serum before treatment in compar-
ison with the control groupsG was significantly
higher (P¼ 0.015), but there was no significant
decline of median values during treatment
(P¼ 0.132) (Fig. 1D, Table 1).
The FEV1 as well as the IVC did not change
significantly during treatment (P¼ 0.085, respec-
tively 0.135; (Table 1)) despite the significant
difference with the control groupG (Po0.001,
respectively 0.001).
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Figure 1 Inflammation and oxidative stress in patients with exacerbated COPD. Measurements of exhaled H2O2 (A), IL-
8 (C), sICAM-1 (D) and sE-selectin (E) were performed at day 1, 3, and 7.
nThere was no significant difference between smokers and
non-smokers (Table 2).
G(see footnote * ).
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Over time, patient 14 showed a gradual increase
of the H2O2 concentration in breath condensate as
well as E-selectin in serum. The concentration of
ICAM-1 was significant increased (Po0.001) com-
pared to the concentrations of ICAM-1 of the other
patients at the three consecutive measurements.
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Table 2 Measurements of exhaled H2O2 in breath condensate, IL-8, sICAM-1, sE-selectin in serum and FEV1 and
IVC by smoking and non-smoking controls.
Marker Smokers (n¼ 15) Non-smokers (n¼ 15) p-value
H2O2 (mM/l) 0.12 [0.08–0.16] 0.00 [0.00–0.00]
n o0.001
IL-8 (ng/l) 4.3 [2.1–5.6] 3.4 [2.1–3.4] 0.683
sICAM-1 (mg/l) 88 [71–109] 97 [69–122] 0.902
sE-selectin (mg/l) 13 [11–19] 11 [9–13] 0.061
FEV1 (% predicted) 96 [88–107] 106 [96–111] 0.425
IVC (% predicted) 108 [90–116] 102 [92–110] 0.614
Data are presented as median [25–75 percentiles], Po0.05 was considered significant.
nResults were obtained by extrapolation.
Table 1 Sequential measurements of exhaled H2O2 in breath condensate, IL-8, sICAM-1, sE-selectin in serum and
FEV1 and IVC, during treatment of patients with an exacerbated COPD.
Day 1 Day 3 Day 7 p-value
H2O2 (mM/l) 0.48 [0.39–0.58] 0.31 [0.26–0.36] 0.23 [0.18–0.36] 0.001
IL-8 (ng/l) 11.0 [5.0–15.5] 8.0 [2.0–9.0] 5.0 [3.0–13.0] 0.002
sICAM-1 (mg/l) 118 [90–150] 97 [80–143] 91 [78–118] o0.001
sE-selectin (mg/l) 17 [12–32] 19 [10–26] 17 [9–32] 0.132
FEV1 (% predicted) 30 [26–47] 38 [28–49] 40 [26–52] 0.085
IVC (% predicted) 67 [37–78] 66 [59–89] 71 [51–85] 0.135
Data are presented as median [25–75 percentiles], Po0.05 was considered significant.
Figure 2 H2O2 concentrations in exhaled breath condensate of the control groups. Data are presented as median [25–
75 percentile].
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Discussion
The H2O2 concentration in breath condensate as
well as IL-8, E-selectin in serum of the patients at
admission were significantly increased, while the
spirometric lung tests FEV1 and IVC where signifi-
cantly decreased compared to the healthy controls
(in both smokers and non-smokers). During treat-
ment H2O2 in breath condensate and IL-8, E-
selectin in serum decreased significantly.
The method applied to measure H2O2 concentra-
tion was valid and reproducible (see study design);
therefore the observed differences between the
consecutive measurements had to originate from
biological mechanisms.
Hydrogen peroxide concentration can be influ-
enced by the intake of food, beverages, smoking,
exercise and an increase over the day.24 Most of
these problems can be avoided by taking samples
before the patient had breakfast at a fixed time
point and a mouthwash with chlorohexidine 0.2%
(see study design).
Dekhuijzen and co-workers reported comparable
amounts of H2O2 in the expired air of unstable
COPD patients.18 During treatment we observed a
highly significant decline. At day 7 the H2O2
concentration in the treated patients resembled
that of stable COPD patients.18
IL-8 in serum is associated with a number of
inflammatory pulmonary diseases in which neutro-
phils are implicated in the pathogenesis of the
disease such as COPD. Increased levels of IL-8 in
sputum as well as in plasma have been found in
patients with COPD. This study showed significantly
raised levels of IL-8 in serum of patients with
exacerbated COPD before treatment compared to
the control groups. Treatment resulted in a
significant decrease of IL-8 during the observation
period however a few patients had levels higher
than normal after 7 days despite treatment. A fair
consumption is that after stopping the prednisolone
iv administration, the inflammatory process casu
quo oxidative stress flared up again despite oral
prednisolone. It is possible that the underlying
inflammation was not completely resolved or a new
inflammation started up during hospital stay.
However, there is evidence that IL-8 production
even occurs in the absence of an acute infection
and may play a significant role in neutrophil
accumulation in the chronic disease process.4,5
An increased expression of the cell adhesion
molecules ICAM-1 and E-selectin in the airways of
patients with COPD has been found.10–12. ICAM-1
and E-selectin in serum are associated with
inflammatory pulmonary reactions. These adhesion
molecules are involved with leukocyte migration
and accumulation at the sight of inflammation.
There is an increased expression of both adhesion
molecules in case of an inflammatory process. With
X-ray, occasionally it may be possibly to detect this
infiltration, however in this study the X-ray showed
no signs of infiltration. Riise et al. detected soluble
cell adhesion molecules ICAM-1 in serum and E-
selectin in bronchoalveolar lavage fluid of patients
with stable COPD.14 We only found significantly
elevated levels of E-selectin in serum in case of
exacerbated COPD in comparison with the control
groups. There were still a few patients at day 7 who
had higher E-selectin levels than the reference
values. Although there was a tendency to decline
during treatment, this was not significant. sICAM-1
in serum of the patients measured at admission
proved to be significantly raised compared to the
control groups. During treatment a significant
decrease in time was found.
Spirometric evaluation showed no significant
changes in IVC and FEV1 after treatment had been
started, however both spirometric parameters gave
an improvement of the lung function (Table 1)
during treatment with prednisolone.
In conclusion, our study clearly demonstrates
enhanced oxidative stress as well as inflammation
in the airways of the patients, admitted at the
hospital because of exacerbated COPD. These
results suggest that higher levels of sICAM-1 in
serum and H2O2 in exhaled breath condensate may
reflect the upregulation of ICAM-1 and H2O2
production due to inflammation. Therefore, we
presume that sICAM-1 in serum and H2O2 in exhaled
breath condensate are useful markers for disease
monitoring in case of exacerbated COPD.
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